ESMO 2026 was the hotspot for cancer research readouts, with encouraging trials across indications and therapeutic candidates ...

For years, macrocyclic drugs have occupied a niche space in the pharmaceutical landscape, offering drugmakers a way to tackle biological targets that conventional small molecules struggle to reach.

Look into the landscape around TROP2 ADCs as frontrunners aim to expand and the next wave aims to develop safer drugs.

In an interview with Labiotech, Jacobs discussed the decisions behind Novavax’s transformation, the economics of its new ...

Delve into the field of B7-H3 ADCs, a new contender in SCLC cancer, as Hansoh Pharma and Medilink bring momentum with ...

Learn when TIDE-based Sanger sequencing can replace NGS for measuring on-target gene editing efficiency in regulated ...

Discover five myopia companies racing to go beyond glasses, as myopia is set to affect half the world by 2050.

Delve into Labiotech's October oncology roundup and find out about the news that caught our attention this last month.

Discover six companies advancing promising treatments for pulmonary hypertension beyond vasodilators, changing the standards of care.

People with polyendocrine metabolic ovarian syndrome (PMOS) are affected by hormone imbalances, impacting everything from mood to fertility. The cause of the condition is unknown, but the recent name ...

Discover Novo's pipeline in 2026, as it recently set out a new plan to reach $23 billion in risk-adjusted pipeline sales by ...

Vision loss remains one of the leading causes of disability worldwide, with millions affected by inherited retinal diseases, age-related macular degeneration, and diabetic eye disease. While existing ...